Status:
COMPLETED
Cardiovascular Evaluation of Adult PHA 1 Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Pseudohypoaldosteronism Type 1
Eligibility:
All Genders
18+ years
Brief Summary
Vascular and cardiac alterations are associated with aldosterone effects are evidenced in experimental models and aldosterone receptor blockade is of clear benefit in cardiac disease (heart failure). ...
Detailed Description
The study includes adult patients with mineralocorticoid receptor mutation as compared with not affected relatives. It includes also relatives of adult relative of patients with PHA1 in whom no mutati...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age over 18
- Male or female gender
- Genotype in the PHA1.NET network
- Exclusion criteria:
- Not membership to a regime of Social Security or to a CMU
- Against indication in the realization of a MRI
- Cardiac NMR not possible
- Known cardiovascular disease for person not carrying MR mutation
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00646828
Start Date
May 1 2008
End Date
May 1 2011
Last Update
January 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Bichat
Paris, France, 75018